Objective: To summarize the evidence of various exercise modalities on population with insomnia disorders. Method: PubMed, Embase, Cochrane Library, and Web of Science were searched for eligible studies published from inception to October 2022 and updated on September 2023. Systematic reviews with meta -analyses and randomized controlled trials designed to investigate the effect of various exercise modalities on population with insomnia were eligible. Results: A total of 4 SRs with (very) low methodological quality and 1034 participants in 10 network metaanalyses explored the association between different types and intensity exercise modalities with insomnia disorders. Various exercise modalities could significantly improve total sleep time and sleep quality and alleviate insomnia severity. Compared to passive control, moderate aerobic exercise, moderate aerobic exercise combined with light intensity strength and mind -body exercise can improve sleep efficiency and reduce wake after sleep onset by objectively measured. Moderate intensity strength, light intensity strength and mind -body exercise can improve sleep efficiency subjectively measured; mind -body exercise can reduce sleep onset latency and wake time after sleep onset, and increase total sleep time; moderate aerobic exercise can reduce sleep onset latency. Moderate intensity strength, light intensity strength, mind body exercise and moderate aerobic exercise combined with light intensity strength can the severity of insomnia and improv sleep quality. Conclusion: Exercise had a positive effect on relief insomnia and improve sleep quality. Moderate aerobic exercise, mind -body exercise and moderate aerobic exercise combined with light intensity strength play an important role in improving the sleep quality in people with insomnia disorders.

Objective: To assess the overall effect of pharmacist-involved medication therapy management (MTM) on patient outcomes and to interpret the assessment for a general population. Methods: Many small studies have documented the influence the pharmacist's role within MTM for specific populations. However, not many studies have documented the impact of the importance of a pharmacist in MTM overall in general populations. A stronger indicator of improved patient outcomes with a pharmacist-led MTM could lead to larger studies and better health care policy in the future. A literature search of published studies (hospital and community settings) was performed in Medline (via PubMed), the International Pharmaceutical Abstracts, and Embase. Studies were also identified from the references in these articles and in reviews. For a study to be included in this meta-analysis, it must have a pharmacist-involved medication intervention. The included studies were published no earlier than January 2009 in developed countries. All studies with less than 50 participants or a follow-up period less than 16 weeks were excluded. The recommendations of Cochrane Collaboration and the Quality of Reporting of Meta-analyses guidelines were also implemented. Results: Preliminary data analysis suggests a significant improvement in patient outcomes with a pharmacist-involved MTM. When observing strictly patient adherence in three previously selected trials, the pharmacist intervention had a 7% greater patient adherence versus the control intervention. Conclusion: NA (research in progress)